2C-N Stats & Data
NCCc1cc(O)c(N(=O)=O)cc1OPYVMPIIVMMPROM-UHFFFAOYSA-NReceptor Profile
Receptor Actions
Effect Profile
Curated + 3 ReportsStrong visuals with moderate body load, low headspace
Community Effects
TripSitTolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Rapid tolerance and cross‑tolerance typical of 5‑HT2A agonists; model based on human/animal literature for classical psychedelics rather than 2C‑N-specific trials; spacing 10–14 days is a prudent rule-of-thumb.
Cross-Tolerances
Experience Report Analysis
ErowidDemographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 3 experience reports (3 Erowid)
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 0
Adverse Effects 1
Real-World Dose Distribution
62K DosesFrom 5 individual dose entries
Form / Preparation
Most common forms and preparations reported
Legal Status
| Country | Status | Notes |
|---|---|---|
| Canada | As of October 31, 2016, 2C-N is a controlled substance (Schedule III) in Canada. | |
| United Kingdom | 2C-N and most (possibly all) other compounds featured in PiHKAL are illegal drugs in the United Kingdom. | |
| United States | In the United States, 2C-N is a Schedule 1 controlled substance. |
Harm Reduction
drugs.wikiEvidence-based harm-reduction additions and corrections (reasoning and citations below): 1) Dosage correction: PIHKAL associates 2C‑N with much higher oral doses than originally listed. Community bioassays report noticeable to fully psychedelic effects at ~100–130 mg (HCl salt), with 60 mg nitrate described as mild. The prior 8–30 mg range risks underdosing and confusing 2C‑N with far more potent NBOMe analogs; corrected to 90–130 mg common range with conservative lower bands. 2) Salt-form potency: One Erowid report explicitly notes the nitrate salt is ~9% less potent than HCl; while anecdotal, users should account for salt mass when weighing. 3) Short duration: Reports consistently describe a shorter total timeline (≈3–5 hours at typical doses), so duration was tightened to 3–6 hours with rapid onset at higher doses. 4) Interaction specifics: TripSit’s combination guidance for 2C‑x supports listing MAOIs as ‘dangerous’, tramadol as ‘unsafe’ (seizure risk), and stimulants/caffeine as cautionary due to cardiovascular and anxiety load; SSRIs/SNRIs may attenuate or unpredictably alter effects. 5) Insufflation caution: Across 2C‑x, insufflation is commonly very painful with greater side effects; oral dosing is strongly preferred for safety and comfort. 6) Misidentification risk: 2C‑N is rare; NBOMes/NBOHs on blotter or as potent sub‑mg powders are sometimes sold as ‘2C‑x’. NBOMes are active at microgram doses and have been linked to medical emergencies; always test and avoid unknown blotters as ‘2C‑N’. 7) Legal risk (U.S.): 2C‑N was added to Schedule I in July 2012, creating substantial legal penalties for possession/distribution. 8) Tolerance: Classic 5‑HT2A psychedelics rapidly produce tolerance within days with cross‑tolerance across LSD/psilocybin/mescaline/DOx; spacing uses by ~10–14 days reduces unpredictable responses. 9) Phenethylamine body load: Some users report mild GI upset, stimulation, or vasoconstriction; avoid combining with vasoconstrictive stimulants and monitor hydration and temperature. 10) Data scarcity: Human data are limited; individual variability is high; start low, weigh accurately, and prefer oral administration.
References
Data Sources
Cited References
Drugs.wiki References
- PiHKAL entry (2C‑N) — identifiers and references
- PubChem CID 10036637 (2,5-Dimethoxy-4-nitrophenethylamine)
- Erowid experience: 2C‑N nitrate, 60 mg oral (mild, short)
- Bluelight: Big & Dandy 2C‑N thread (130 mg oral, active)
- Bluelight: Trip report 2C‑N 100 mg HCl (first time)
- TripSit drug combinations (2C‑x with MAOIs, tramadol, stimulants, caffeine)
- Erowid legal pages referencing 2012 US Schedule I additions (includes 2C‑N)
- Nichols 2016 review: rapid tolerance via 5‑HT2A downregulation; cross‑tolerance evidence
- PubMed 2022: cross‑tolerance among psychedelics; 5‑HT2A involvement
- Erowid NBOMe series: potency, risks and misidentification concerns